A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

This is the first report describing a rapid increase in hemoglobin after pausing alectinib and no relapse of hemolysis after switching to lorlatinib, while the lung cancer remained stable (stable disease).

Authors

Institutions

Publication Details

Journal
Case Reports in Oncology
Published
2025-10-09
DOI
https://doi.org/10.1159/000548479
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

Cornelius F. Waller, X. Tonnar
1 citations
Case Reports in Oncology
Lung Cancer Treatments and Mutations
1.52
article

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

Cornelius F. Waller, X. Tonnar
article en
1 citations

Abstract

This is the first report describing a rapid increase in hemoglobin after pausing alectinib and no relapse of hemolysis after switching to lorlatinib, while the lung cancer remained stable (stable disease).

Case Reports in OncologyVol. 18(1)
University of Freiburg (DE), University Medical Center Freiburg (DE)
Albert-Ludwigs-Universität Freiburg
Openalex Percentile: Top 12%
Lung Cancer Treatments and Mutations
1.52
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.